gip and glp 1 receptor agonist Targeting GLP-1, & GCG in Obesity Type 2 Diabetes Research Dual and Triple Gut Peptide

While semaglutide may not be as powerful as its successors, it remains a valuable and effective option for many patients

A global federated real-world data and analytics platform for research

Third, the optimal positioning and sequencing of GLP-1-based therapies relative to resmetirom and other emerging MASH agents (e.g., lanifibranor, pegozafermin, semaglutide combination regimens) requires dedicated combination trials, of which preliminary data from the MAESTRO-NASH secondary analysis are encouraging

In fact, the inspiration for this article comes from both seeing remarkable anecdotal accounts from people on these drugs, but also the recent trials of Tirzepatide and Taltz showing actual benefit

The SUMMIT trial demonstrated that tirzepatide significantly reduced the risk of HF hospitalisation or an urgent visit requiring intravenous diuretics

Clearly, there has been a need for a new class of antidiabetic agents with advantages over currently marketed drugs that can lower glucose via mechanisms resulting in either neutral or protective effects on the cardiovascular system